Literature DB >> 8862128

Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG, and SGPG in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.

N Yuki1, Y Tagawa, S Handa.   

Abstract

Unlike CNS myelin, human peripheral nerve myelin has the acidic glycosphingolipids sialosyl paragloboside (SPG), sialosyl lactosaminyl paragloboside (SLPG), and sulfated glucuronyl paragloboside (SGPG). To elucidate the pathogenesis of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating neuropathy (CIDP), we investigated the autoantibodies to peripheral nerve molecules in patients with these diseases and compared the frequency of the autoantibodies with that of autoantibody to GM1 which is present in both the CNS and PNS. The report of Sheikh et al. (Ann. Neurol. 1995; 38: 350) that Campylobacter jejuni bears the SGPG epitope led us to study whether sera from patients with GBS subsequent to C. jejuni enteritis have anti-SGPG antibody; but, high anti-SGPG antibody titers were not found in the GBS patients from whom C. jejuni was isolated. Although the frequency of the anti-SPG, anti-SLPG and anti-SGPG antibodies were lower than that of the anti-GM1 antibody in GBS, 5 patients with demyelinating GBS had high IgG anti-SPG antibody titers. IgG anti-SPG antibody may function in the development of demyelinating GBS. We found that 6 CIDP patients had elevated IgM anti-SGPG antibody titers. Immunoelectrophoresis failed to detect IgM M-protein in 3 of the patients. IgM anti-SGPG antibody could be a diagnostic marker for a subgroup of CIDP with or without paraprotein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862128     DOI: 10.1016/s0165-5728(96)00042-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

Review 1.  Chronic inflammatory demyelinative polyneuropathy.

Authors:  Gérard Said
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

Review 2.  Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases.

Authors:  Robert K Yu; Seigo Usuki; Toshio Ariga
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

Review 3.  Clinical utility of autoantibodies in Guillain-Barre syndrome and its variants.

Authors:  J W Terryberry; Y Shoenfeld; J B Peter
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 4.  Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders.

Authors:  Panos Stathopoulos; Harry Alexopoulos; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-27       Impact factor: 42.937

5.  Neurologic symptoms associated with cattle farming in the agricultural health study.

Authors:  Leora Vegosen; Meghan F Davis; Ellen Silbergeld; Patrick N Breysse; Jacqueline Agnew; Gregory Gray; Laura Beane Freeman; Freya Kamel
Journal:  J Occup Environ Med       Date:  2012-10       Impact factor: 2.162

6.  Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes.

Authors:  Nortina Shahrizaila; Norito Kokubun; Setsu Sawai; Thirugnanam Umapathi; Yee-Cheun Chan; Satoshi Kuwabara; Koichi Hirata; Nobuhiro Yuki
Journal:  Neurology       Date:  2014-06-11       Impact factor: 9.910

Review 7.  Immunological Outcomes of Antibody Binding to Glycans Shared between Microorganisms and Mammals.

Authors:  Preeyam Patel; John F Kearney
Journal:  J Immunol       Date:  2016-12-01       Impact factor: 5.422

8.  Clinical syndromes associated with tomacula or myelin swellings in sural nerve biopsies.

Authors:  S Sander; R A Ouvrier; J G McLeod; G A Nicholson; J D Pollard
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

9.  Molecular mimicry: its evolution from concept to mechanism as a cause of autoimmune diseases.

Authors:  Michael B A Oldstone
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-04-02

10.  Noteworthy Neurological Manifestations Associated With COVID-19 Infection.

Authors:  Adam C Kaplan
Journal:  Cureus       Date:  2021-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.